Protein drug delivery to retina and choroid

Ocular Drug Delivery Systems: Barriers and Application of Nanoparticulate Systems

Volumn , Issue , 2012, Pages 191-213

  Rivers, Hongwen M ^a   Hughes, Patrick M ^a  

^a ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85017157560     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b12950     Document Type: Chapter

References (140)

1. Parkinson J. The promise of ocular implants. Retinal Physician. 2005; 2: 79-84.
2. Short BG. Safety evaluation of ocular drug delivery formulations: Techniques and prac-tical considerations. Toxicol Pathol. 2008; 36: 49-62.
3. Gaudana R, Jwala J, Boddu SHS, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res. 2009; 26: 1197-1216.
4. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007; 114: 855-859.
5. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007; 114: 2179-2182.
6. Herrero-Vanrell R, Refojo MF. Biodegradable microspheres for vitreoretinal drug deliv-ery. Adv Drug Deliv Rev. 2001; 52: 5-16.
7. van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res. 2000; 17: 1159-1167.
8. Houchin ML, Topp EM. Chemical degradation of peptides and proteins in PLGA: A review of reactions and mechanisms. J Pharm Sci. 2008; 97: 2395-2404.
9. Crotts G, Park TG. Protein delivery from poly(lactic-co-glycolic acid) biodegrad-able microspheres: Release kinetics and stability issues. J Microencapsul 1998; 15: 699-713.
10. Barcia E, Herrero-Vanrell R, Díez A, Alvarez-Santiago C. Downregulation of endo-toxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) micro-spheres loaded with dexamethasone. Exp Eye Res. 2009; 89: 238-245.
11. Moritera T, Ogura Y, Yoshimura N, Honda Y, Wada R, Hyon SH, Ikadat Y. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopath. Invest Ophthalmol Vis Sci. 1992; 33: 3125-3130.
12. Saisbin Y, Silva RL, Saisbin Y, Callaban K, Schoch C, Ablbeim M, Lai H et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci 2003; 44: 4989-4993.
13. Garrasquillo KG, Ricker JA, Rigas IK, Miller JW, Gragoudas ES, Adamis AP. Controlled delivery of the antiVEGF aptemer EYE001 with poly(lactic-co-glycolic) acid micro-spheres. Invest Ophthalmol Vis Sci 2003; 44: 290-299.
14. Moritera T, Ogura Y, Yoshimura N, Kuriyama S, Honda Y, Tabata Y, Ikada Y. Feasibility of drug targeting to the retinal pigment epithelium with biodegradable microspheres. Curr Eye Res. 1994; 13: 171-176.
15. Moritera T, Ogura Y, Honda Y, Wada R, Hyon SH, Ikadat Y. Microspheres of biode-gradable polymers as a drug-delivery system in the vitreous. Invest Ophthalmol Vis Sci. 1991; 32: 1785-1790.
16. Mordenti J, Thomsen K, Licko V, Berleau L, Kahn JW, Cuthbertson RA, Duenas ET et al. Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rab-bits after intravitreal administration of a solution or a PLGA microsphere formulation. Toxicol Sci 1999; 52: 101-106.
17. Eljarrat-Binstock E, Pe’er J, Domb AJ. New techniques for drug delivery to the posterior eye treatment. Pharm Res. 2010; 27: 530-543.
18. del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today. 2008; 13: 135-143.
19. Sanders LM, Kent JS, McRae GI, Vickery BH, Tice TR, Lewis DH. Controlled release of a luteinizing hormone-releasing hormone analogue from poly(d, l-lactide-co-gly-colide) microspheres. J Pharm Sci. 1984; 73: 1294-1297.
20. Kang F, Singh J. Effects of additives on the release of model protein from PLGA micro-spheres. AAPS PharmSciTech. 2001; 2:1-7.
21. Schwendeman SP, Tobio M, Joworowicz M, Alonso MJ, Langer R. New strategies for the microencapsulation of tetanus vaccine. J Microencapsul. 1998; 15: 299-318.
22. Bartus RT, Tracey MA, Emerich DE, Zale SE. Sustained delivery of proteins for novel therapeutic products. Science. 1998; 281: 1161-1162.
23. Herbert P, Murphy K, Johnson O, Dong N, Jaworowicz W, Tracey MA, Cleland H, Putney SD. A large-scale process to produce microencapsulated proteins. Pharm Res. 1998; 15: 357-361.
24. Morita T, Sakamura Y, Horikiri Y, Sukuki T, Yoshino H. Protein encapsulation into bio-degradable microspheres by a novel S/O/W emulsion method using poly(ethylene gly-col) as a protein micronization adjuvant. J Control Release. 2000; 69: 435-444.
25. Castellanos IJ, Crespo R, Griebenow K. Poly(ethylene glycol) as stabilizer and emulsi-fying agent: A novel stabilization approach preventing aggregation and inactivation of proteins upon encapsulation in bioerodible polyester microsphere. J Control Release. 2003; 88: 135-145.
26. Lee ES, Kwon MJ, Lee H, Na K, Kim JJ. In vitro study of lysozyme in poly(lactide-co-glycolide) microspheres with sucrose acetate isobutyrate. Eur J Pharm Sci. 2006; 29: 435-441.
27. Nam YS, Song SH, Choi JY, Park TG. Lysozyme microencapsulation within biode-gradable PLGA microspheres: Urea effect on protein release and stability. Biotechnol Bioeng. 2000; 70: 270-277.
28. Li JK, Wang N, Wu XS. A novel biodegradable system based on gelatin nanoparticles and poly(lactic-co-glycolic acid) microspheres for protein and peptide drug delivery. J Pharm Sci. 1997; 86: 891-895.
29. Li, SH, Cai SX, Liu B, Ma KW, Wang ZP, Li XK. In vitro characteristics of poly (lactic-co-glycolic acid) microspheres incorporating gelatin particles loading basic fibroblast growth factor. Acta Pharmacol Sin. 2006; 27: 754-759.
30. Zhou S, Deng X, He S, Li X, Jia W, Wei D, Zhang Z, Ma J. Study on biodegradable microspheres containing recombinant interferon-f-2α. J Pharm Pharmacol. 2002; 54: 1287-1292.
31. Wang N, Wu XS, Li JK. A heterogeneously structured composite based on poly (lactic-co-glycolic acid) microspheres and poly (vinyl alcohol) hydrogel nanospheres for long-term protein drug delivery. Pharm Res. 1999; 16: 1430-1435.
32. Yuan W, Wu F, Jin T. Microencapsulation of protein-loaded polysaccharide particles within poly(D, L-lactic-co-glycolic acid) microspheres using S/O/W: Characterization and release studies. Polym Adv Technol. 2009; 20: 834-842.
33. Estey T, Kang J, Schwendeman SP, Carpenter JF. BSA degradation under acidic condi-tions: A model for protein instability during release from PLGA delivery systems. J Pharm Sci. 2006; 95: 1626-1639.
34. Lucke A, Göpferich A. Acylation of peptides by lactic acid solutions. Eur J Pharm Biopharm. 2003; 55: 27-33.
35. Mariette B, Coudane J, Vert M, Gautier J-C, Moneton P. Release of the GRF29NH2 analog of human GRF44NH2 from a PLA/GA matrix. J Control Release. 1993; 24: 237-246.
36. Giteau A, Venier-Julienne MC, Aubert-Pouëssel A, Benoit JP. How to achieve sus-tained and complete protein release from PLGA-based microparticles? Int J Pharm. 2008; 350: 14-26.
37. Kim HK, Park TG. Microencapsulation of human growth hormone within biodegrad-able polyester microspheres: Protein aggregation stability and incomplete release mech-anism. Biotechnol Bioeng. 1999; 65: 659-667.
38. Houchin ML, Heppert K, Topp EM. Deamination, acylation and proteolysis of a model peptide in PLGA films. J Control Release. 2006; 112: 111-119.
39. Breitenbach A, Kissel T. Biodegradable comb polyesters: Part I. Synthesis, characteriza-tion and structural analysis of poly(lactide) and poly(lactide-co-glycolide) grafted onto water-soluble poly(vinyl alcohol) as backbone. Polymer. 1998; 39: 3261-3271.
40. Breitenbach A, Pistel KF, Kissel T. Biodegradable comb polyesters: Part II. Erosion and release properties of poly(vinyl alcohol)-g-poly(lactic-co-glycolic acid. Polymer. 2000; 41: 4781-4792.
41. Pistel KF, Breitenbach A, Regina Z-V, Kissel T. Brush-like branched biodegradable polyesters: Part III. Protein release from microspheres of poly (vinyl alcohol)-grafted-poly(D, L-lactic-co-glycolic acid). J Control Release. 2001; 73: 7-20.
42. Li X, Zhang Y, Yan R, Jia W, Yuan M, Deng X, Huang Z. Influence of process param-eters on the protein stability encapsulated in poly-DL-lactide-poly(ethylene glycol) microspheres. J Control Release. 2000; 68: 41-52.
43. Zhu G, Schwendeman SP. Stabilization of proteins encapsulated in cylindrical poly(lactide-co-glycolide) implants: Mechanism of stabilization by basic additives. Pharm Res. 2000; 17: 351-357.
44. Zhu G, Mallery SR, Schwendeman SP. Stabilization of proteins encapsulated in inject-able poly(lactide-co-glycolide). Nat Biotechnol. 2000; 18: 52-57.
45. Gao H, Wang YN, Fan YG, Ma JB. Conjugates of poly(DL-lactide-co-glycolide) on amino cyclodextrins and their nanoparticles as protein delivery system. J Biomed Mater Res A. 2006; 80: 111-122. doi: 10.1002.
46. De Leede LG, Humphries JE, Bechet AC, Van Hoogdalem EJ, Verrijk R, Spencer DG. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): Pharmacokinetics, pharmacodynamics, and tolerability in phase I clinical trial. J Interferon Cytokine Res 2008; 28: 113-122.
47. Steendam R, van der Laan A, Hissink D. Bioresorbable drug-eluting stent coating formulations based on SynBioysys biodegradable multi-block copolymers. J Control Release. 2006; 116: e94-e95.
48. Rothen-Weinhold A, Schwach-Abdellaoui K, Barr J, Ng SY, Shen HR, Gurny R, Heller J. Release of BSA from poly(ortho ester) estruded thin strands. J Control Release. 2001; 71: 31-37.
49. van de Weert M, van Steenbergen MJ, Cleland JL, Heller J, Hennink WE, Crommelin DJA. Semisolid, self-catalyzed poly(ortho ester) as controlled-release systems: Protein release and protein stability issues. J Pharm Sci. 2002; 91: 1065-1074.
50. Heller J, Barr J. Poly(ortho esters)-from concept to reality. Biomacromolecules. 2004; 5: 1625-1632.
51. Uebersax L, Mattotti M, Papaloïzos M, Merkle HP, Gander B, Meinel L. Silk fibroin matrices for the controlled release of nerve growth factor (NGF). Biomaterials. 2007; 28: 4449-4460.
52. Hofmann S, Foo CT, Rossetti F, Textor M, Vunjak-Novakovic G, Kaplan DL, Merkle HP, Meinel L. Silk fibroin as an organic polymer for controlled drug delivery. J Control Release. 2006; 111: 219-227.
53. Wang X, Yucel T, Lu Q, Hu X, Kaplan DL. Silk nanospheres and microspheres from silk/pva blend films for drug delivery. Biomaterials. 2010; 31: 1025-1035.
54. Wang X, Wenk E, Matsumoto A, Meinel L, Li C, Kaplan DL. Silk microspheres for encapsulation and controlled release. J Control Release. 2007; 117: 360-370.
55. Wenk E, Wandrey AJ, Merkle HP, Meinel L. Silk fibroin spheres as a platform for con-trolled drug delivery. J Control Release. 2008; 132: 26-34.
56. Bikram M, West JL. Thermo-responsive systems for controlled drug delivery. Expert Opin Drug Deliv. 2008; 5: 1077-1091.
57. Betre H, Liu W, Zalutsky MR, Chilkoti A, Kraus VB, Setton LA. A thermally respon-sive biopolymer for intra-articular drug delivery. J Control Release. 2006; 115: 175-182.
58. Mundada AS, Avari, JG. In situ gelling polymers in ocular drug delivery systems: A review. Crit Rev Ther Drug Carrier Syst. 2008; 26: 85-118.
59. Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Chitosan and its role in ocular therapeutics. Mini Rev Med Chem. 2009; 9: 1639-1647.
60. Bhattarai N, Ramay HR, Gunn J, Matsen FA, Zhang M. PEG-grafted chitosan as an injectable thermosensitive hydrogel for sustained protein release. J Control Release. 2005; 103: 609-624.
61. Cohen S, Lobel E, Trevgoda A, Peled Y. A novel in situ-forming ophthalmic drug deliv-ery system from alginate undergoing gelation in the eye. J Control Release. 1997; 44: 201-208.
62. Yawei N, Kenneth MY. In-situ gel formation of pectin. US patent no. 6,777,000 B2. 2004.
63. Bos GW, Jacobs JJL, Koten JW, Van Tomme S, Veldhuis T, van Nostrum CF, Otter WD, Hennink WE. In situ crosslinked biodegradable hydrogels loaded with IL-2 are effective tools for local IL-2 therapy. Eur J Pharm Sci 2004; 21: 561-567.
64. Van Tomme SR, De Geest BG, Braeckmans K, De Smedt SC, Siepmann F, Siepmann J, van Nostrum CF, Hennink WE. Mobility of model proteins in hydrogels composed of oppositely charged dextran microspheres studied by protein release and fluorescence recovery after photobleaching. J Control Release 2005; 110: 67-78.
65. Amrite AC, Kompella UB. Nanoparticles and microparticles: Particle engineering, cell uptake, in vivo disposition & efficacy. Drug Deliv Technol. 2007; 7: 52-56.
66. Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. Polymeric nanoparticulate system: A potential approach for ocular drug delivery. J Control Release. 2009; 136: 2-13.
67. Bourges JL, Gautier SE, Delie F, Bejjani RA, Jeanny JC, Gurny R, BenEzra D, Behar-Cohen FF. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci. 2003; 44: 3562-3569.
68. Bejjani RA, BenEzra D, Cohen H, Rieger J, Andrieu C, Jeanny JC, Gollomb G, Behar-Cohen FF. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol. Vis. 2005; 11: 124-132.
69. Balasubramanian V, Onaca O, Enea R, Hughes DW, Palivan CG. Protein delivery: From conventional drug delivery carriers to polymeric nanoreactors. Expert Opin Drug Deliv. 2010; 7: 63-78.
70. Choi SH, Park TG. G-CSF loaded biodegradable PLGA nanoparticles prepared by a single oil-in-water emulsion method. Int J Pharm. 2006; 311: 223-228.
71. Li YP, Pei YY, Zhang XY, Gu ZH, Zhou ZH, Yuan WF, Zhou JJ, Zhu JH, Gao XJ. PEGylated PLGA nanoparticles as protein carriers: Synthesis, preparation and biodistri-bution in rats. J Control Release. 2001; 71: 203-211.
72. Caliceti P, Salmaso S, Elvassore N, Bertucco A. Effective protein release from PEG/PLA nano-particles produced by compressed gas anti-solvent precipitation techniques. J Control Release 2004; 94: 195-205.
73. Gan Q, Wang T. Chitosan nanoparticle as protein delivery carrier-Systemic examination of fabrication conditions for efficient loading and release. Colloids Surf B Biointerfaces. 2007; 59: 24-34.
74. Pan Y, Li Y, Zhao H, Zheng J, Xu H, Wei G, Hao J, Cui F. Bioadhesive polysaccharide in protein delivery system: Chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 2002; 249: 139-147.
75. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev. 2007; 59: 478-490.
76. Fundarò A, Cavalla R, Bargoni A, Vighetto D, Zara GP, Gasco MR. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: Pharmacokinetics and tis-sue distribution after i.v. administration to rats. Pharm Res. 2000; 42: 337-343.
77. Zara GP, Cavalli R, Bargoni A, Fundarò A, Vighetto D, Gasco MR. Intravenous adminis-tration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: Pharmacokinetics and distribution of doxo-rubicin in brain and other tissues. J Drug Target 2007; 10: 327-335.
78. Reithmeier H, Herrmann J, Göpferich A. Lipid microparticles as a parental controlled release device for peptides. J Control Release. 2001; 73: 339-350.
79. Reithmeier H, Herrmann J, Göpferich A. Development and characterization of lipid microparticles as a drug carrier for somatostatin. Int J Pharm. 2001; 218: 133-143.
80. Chan YP, Meyrueix R, Kravtzoff R, Nicolas F, Lundstrom K. Review on Medusa®: A polymer-based sustained release technology for protein and peptide drugs. Expert Opin Drug Deliv. 2007; 4: 441-451.
81. Shimizu T, Kishida T, Hasegawa U, Ueda Y, Imanishi J, Yamagishi H, Akiyoshi K, Otsuji E, Mazda O. Nanogel DDS enables sustained release of IL-12 for tumor immu-notherapy. Biochem Biophys Res Commun 2008; 367: 330-335.
82. Van Slooten ML, Boerman O, RomØren K, Kedar E, Crommelin DJ, Storm G. Liposomes as sustained release system for human interferon-gamma: Biopharmaceutical aspects. Biochim Biophys Acta. 2001; 1530: 134-145.
83. Allen TM, Mehra T, Hansen C, Chin YC. Stealth liposomes: An improved sus-tained release system for 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1992; 52: 2431-2439.
84. Wiechens B, Neumann D, Grammer JB, Pleyer U, Hedderich J, Duncker GIW. Retinal toxicity of liposome-incorporated and free ofloxacin after intravitreal injection in rabbit eyes. Int Ophthalmol. 1999; 22: 133-143.
85. Zhang R, He R, Qian J, Guo J, Xue K, Yuan Y. Treatment of experimental autoim-mune uveoretinitis with intravitreal injection of Tacrolimus (FK506) encapsulated in liposomes. Invest Ophthalmol Vis Sci. 2010; 51: 3575-3582.
86. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008; 13: 144-151.
87. Mantripragada S. A lipid based Depot (DepoFoam® technology) for sustained release drug delivery. Prog Lipid Res. 2002; 41: 392-406.
88. Yatuv R, Robinson M, Dayan I, Baru M. Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes: A case of FVIII, FVIIa and G-CSF. Expert Opin Drug Deliv. 2010; 7: 187-201.
89. Lee KY, Yuk SH. Polymeric protein delivery systems. Prog Polym Sci. 2007; 32: 669-697.
90. Baltmr A, Duggan J, Nizari S, Salt TE, Cordeiro MF. Neuroprotection in glaucoma-Is there a future role? Exp Eye Res 2010; 91: 554-566.
91. Lambiase A, Aloe L, Centofanti M, Parisi V, Mantelli F, Colafrancesco V, Manni GL, Bucci MG, Bonini S, Lei-Montalcini R. Experimental and clinical evidence of neuro-protection by nerve growth factor eye drops: Implications for glaucoma. Proc Natl Acad Sci USA 2009; 106: 13469-13474.
92. Jiang C, Moore MJ, Zhang X, Klassen H, Langer R, Young M. Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glau-coma. Mol Vis. 2007; 13: 1783-1792.
93. Naskar R, Vorwerk C, Dreyer EB. Concurrent downregulation of a glutamate transporter and receptor in glaucoma. Invest Ophthalmol Vis Sci. 2000; 41: 1940-1944.
94. Pease ME, Zack DJ, Berlinicke C, Bloom K, Cone F, Wang Y, Klein EL, Hauswirth WW, Quigley HA. Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Invest Ophthalmol Vis Sci. 2009; 50: 2194-2200.
95. Cui Q, Harvey AR. At least two mechanisms are involved in the death of retinal ganglion cells following target ablation in neonatal rats. J Neurosci. 1995; 15: 8143-8155.
96. Schuettauf F, Zurakowski D, Quinto K, Varde MA, Besch D, Laties A, Anderson R, Wen R. Neuroprotective effects of cardiotrophin-like cytokine on retinal ganglion cells. Graefes Arch Clin Exp Ophthalmol 2005; 243: 1036-1042.
97. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signaling cascade. Nature. 2001; 412: 641-647.
98. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S, Rosenbaum PS, Cerami A, Brines M, Rosenbaum DM. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 2002; 99: 10659-10664.
99. Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K, Kaneko H et al. CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature. 2009; 460: 225-231.
100. Lambiase A, Mantelli F, Bonini S. Nerve growth factor eye drops to treat glaucoma. Drug News Perspect. 2010; 23: 361-367.
101. Bonini S, Lambiase A, Rama P, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology 2000; 107: 1347-1351.
102. Lambiase A, Rama P, Bonini S, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med. 1998; 338: 1174-1180.
103. Origlieri C, Bielory L. Emerging drugs for conjunctivitis. Expert Opin Emerg Drugs 2009; 14: 523-536.
104. Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2009; 20: 158-165.
105. Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: Potential therapies. Drugs 2008; 68: 1029-1036.
106. Rodrigues EB, Farah ME, Maia M, Penha FM, Regatieri C, Melo GB, Pinheiro MM, Zanetti CR. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009; 28: 117-144.
107. Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol 2006; 34: 365-374.
108. Penha FM, Rodrigues EB, Maia M, Furlani BA, Regatieri C, Melo GB, Magalhães O Jr., Manzano R, Farah ME. Retinal and ocular toxicity in ocular application of drugs and chemicals-Part II: Retinal toxicity of current and new drugs. Opthalmic Res 2010; 44: 205-224.
109. Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, Feldman BM, Laxer RM, Schneider R, Silverman ED. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford). 2006; 45: 982-989.
110. Shome D, Esmaeli B. Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa. Curr Opin Ophthalmol 2008; 19: 414-421.
111. Bourges JL, Bloquel C, Thomas A, Froussart F, Bochot A, Azan F, Gurny R, BenEzra D, Behar-Cohen F. Intraocular implants foe extended drug delivery: Therapeutic applica-tions. Adv Drug Deliv Rev 2006; 58: 1182-1202.
112. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone aceton-ide implant (Retisert) for noninfectious posterior uveitis: Thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006; 113: 1020-1027.
113. Kane FE, Burdan J, Cutino A, Green KE. Iluvien: A new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008; 5: 1039-1046.
114. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125: 309-317.
115. Wright JC, Tao Leonard S, Stevenson CL, Beck JC, Chen G, Jao RM, Johnson PA, Leonard J, Skowronski RJ. An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J Control Release. 2001; 75: 1-10.
116. Hutchinson FG, Furr BJA. Biodegradable polymers for the sustained release of peptides. Biochem Soc Trans. 1985; 13: 502-523.
117. Furr BJA, Hutchinson FG. A biodegradable delivery system for peptides: Preclinical experience with the gonadotrophin-releasing hormone agonist. J Control Release 1992; 21: 117-128.
118. Ghassemi AH, Steenbergen MJV, Talsma H, van Nostrum CF, Jiskoot W, Crommelin DJA, Hennink WE. Preparation and characterization of protein loaded microspheres based on a hydroxylated aliphatic polyester, poly(lactic-co-hydroxymethyl glycolic acid). J Control Release 2009; 138: 57-63.
119. Sun L, Zhou S, Wang W, Su Q, Li X, Weng J. Preparation and characterization of protein-loaded polyanhydrides microspheres. J Mater Sci Mater Med 2009; 20: 2035-2042.
120. Dziubla TD, Shuvaev VV, Hong NK, Hawkins BJ, Madesh M, Takano H, Simone E et al. Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. Biomaterials 2008; 29: 215-227.
121. Hasadsri L, Kreuter J, Hattori H, Iwasaki T, George JM. Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem 2009; 284: 6972-6981.
122. Leong KW, D’Amore PD, Marletta M, Langer R. Bioerodible polyanhydrides as drug-carrier matrices. II. Biocompatibility and chemical reactivity. J Biomed Mater Res. 1986; 20: 51-64.
123. Rathbone MJ. Modified-Release Drug Delivery Technology, 2nd ed., vol. 2, Drugs and the Pharmaceutical Sciences. New York: Informa Healthcare, 2008, 155.
124. Zenter GM, Rathi R, Shih C, McRea JC, Seo MH, Oh H, Rhee BG et al. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release. 2001; 72: 203-215.
125. Qiao M, Chen D, Hao T, Zhao X, Hu H, Ma X. Injectable thermosensitive PLGA-PEG-PLGA triblock copolymers-based hydrogels as carriers for interleukin-2. Pharmazie. 2008; 63: 27-30.
126. Kim, YJ, Choi S, Koh JJ, Lee M, Ko, KS, Kim SW. Controlled release of insulin from injectable biodegradable triblock copolymer. Pharm Res. 2001; 18: 548-550.
127. Zentner GM. Biodegradable, thermally reversible gels for drug delivery. In The 9th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, UT, 22/22/99-2/25/99.
128. Al-Tahami K, Singh J. Smart polymer based delivery systems for peptides and proteins. Recent Pat Drug Deliv Formul. 2007; 1: 65-71.
129. Singh S, Webster DC, Singh J. Thermosensitive polymers: Synthesis, characterization, and delivery of proteins. Int J Pharm 2007; 341: 68-77.
130. Molina I, Li SM, Martinez MB, Vert M. Protein release from physically cross-linked hydrogels of the PLA/PEO/PLA triblock copolymer-type. Biomaterials. 2001; 22: 363-369.
131. Wang B, Zhu W, Zhang Y, Yang ZG, Ding JD. Synthesis of a chemically cross-linked thermo-sensitive hydrogel film and in situ encapsulation of model protein drugs. React Funct Polym. 2006; 66: 509-518.
132. Park SY, Chung HJ, Lee Y, Park TG. Injectable and sustained delivery of human growth hormone using chemically modified Pluronic copolymer hydrogels. Biotechnol J 2008; 3: 1-7.
133. Chung HJ, Lee Y, Park TG. Thermo-sensitive and biodegradable hydrogels based on stereocomplexed pluronic multi-block copolymers for controlled protein delivery. J Control Release. 2008; 127: 22-30.
134. Hyun H, Kim YH, Song IB, Lee JW, Kim MS, Khang G, Park K, Lee HB. In vitro and in vivo release of albumin using a biodegradable MPEG-PCL diblock copolymer as an in situ gel-forming carrier. Biomacromolecules. 2007; 8: 1093-1100.
135. Nguyen MK, Lee DS. Injectable biodegradable hydrogels. Macromol Biosci. 2010; 10: 563-579.
136. Seong JY, Jun YJ, Kim BM, Park YM, Sohn YS. Synthesis and characterization of bio-compatible poly(organophosphazenes) aiming for local delivery of protein drugs. Int J Pharm. 2006; 314: 90-96.
137. Kang GD, Song SC. Effect of chitosan on the release of protein from thermosensitive poly(organophosphazene) hydrogels. Int J Pharm. 2008; 349: 188-195.
138. Kang Derwent JJ, Mieler WF. Thermosensitive hydrogels as a new ocular drug deliv-ery platform to the posterior segment of the eye. Tans Am Ophthalmol Soc. 2008; 106: 206-213.
139. Cao Y, Zhang C, Shen W, Cheng Z, Yu L, Ping Q. Poly(N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery. J Control Release. 2007; 120: 186-194.
140. Loh XJ, Goh SH, Li J. Hydrolytic degradation and protein release studies of thermogel-ling polyurethane copolymers consisting of poly[(R)-3-hydroxybutyrate], poly(ethylene glycol), and poly(propylene glycol). Biomaterials. 2007; 28: 4113-4123.